

ISMPP Volunteer Reviewer Feedback on GPP 2022: Comments on Patients, Enhanced Content and PLS



Dikran Toroser¹, Laura Dormer², Lisa DeTora³, Eline Hanekamp⁴, and Leslie Citrome⁵

¹Merck & Co Inc, US; ²Becaris Publishing, UK; ³Hofstra University, US; ⁴Excerpta Medica, NL; ⁵New York Medical College, US.

BACKGROUND

- Publications of pharmaceutical company research are varied in nature and may not be easily accessible to a diverse audience that has a real need, interest, and desire to access current scientific and healthcare information
- During the development of GPP 2022, important information was added to accommodate recent advances and trends in publishing, including:
 - Diversity, Equity & Inclusivity (DE&I)
 - Patient involvement in publications
 - Enhanced Content (EC)
 - Plain Language Summaries (PLS)
- The GPP 2022 authors solicited feedback from the ISMPP community via an online collection tool that limited the number of comments and characters. Volunteers collated comments from within their organizations
- A post-hoc review of these comments is reported here

METHODS


- Three GPP 2022 authors used comments delivered from the online collection tool via an Excel spreadsheet to identify content related to DE&I, patient involvement in publications, EC, and PLS

RESULTS

Topline reviewer demographics


- 118 unique sets of comments were available in the data collection tool
- 90/118 (76.3%) of reviewers identified themselves as either Agency or Pharmaceutical company affiliated (**Figure 1**)

Figure 1. Reviewer affiliations



- Volunteer ISMPP reviewers working in North America submitted to 64/118 comment sets (contributors listed their locations in the collection tool; business location was confirmed via LinkedIn) (**Figure 2**)
- Relative frequency of key terms in reviewer responses is indicated in **Figure 3**

Figure 2. Reported reviewer locations



Some submitting reviewers selected multiple locations for multiple contributing reviewers; locations were provided for 137 reviewers contributing to a total of 118 comment sets.

Figure 3. Keyword relative frequency



Diversity, Equity & Inclusion

- In total, 130 comments on DE&I were identified in the reviewer comments (**Figure 4**, **Figure 5**)

Patients

- “Patient” was mentioned 47 times (**Figure 3**) and “patient author” 12 times
- Comments focused on the following topics
 - the need for guidance on the affiliation of patient authors
 - confidentiality
 - scientific qualification to author papers

Enhanced content and Plain language summaries

- EC comments addressed the need for
 - review and approval
 - defining types of EC
- 58 reviewers commented on PLS and generally agreed that:
 - it is good to seek out patient and patient advocate voices
 - patients are not the only audience for PLS

Figure 4. Incidence of keywords around DE&I in the raw comments





Figure 5. Direct quotes from reviewers on DE&I, PLS, and EC



LIMITATIONS

- Over 75% of reviewers identified themselves as either Agency or Pharmaceutical company affiliated, limiting generalizability to other stakeholders

DISCUSSION

- GPP 2022 comments support the need to build inclusivity into the publication process
- This is consistent with the ongoing active DE&I focus at pharmaceutical companies
- Confidentiality for patients was a concern among commenters
- Comments on PLS and EC suggest the need for additional clarifications/guidance, which may suggest a trend for integrating PLSs into publication plans
- Further work is needed to assess integration and reception of GPP 2022 among ISMPP members and their colleagues

Acknowledgements: We thank the GPP 2022 Steering Committee and all GPP 2022 reviewers for their contributions. Poster design support was provided by Cootje Members of Excerpta Medica. **Disclosure:** The views expressed in this poster are those of the authors and do not necessarily represent those of their current or past employers.

References: DeTora, Toroser, Sykes, Vanderlinden, Plunkett, Lane, Hanekamp, Dormer, DiBiasi, Bridges, Baltzer, Citrome (2022) Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann Intern Med. 176(3):eL220490. doi: 10.7326/L22-0490.